Brief: Adverum Biotechnologies Granted Innovative Licensing In The UK For Ixo-Vec For The Treatment Of Wet AMD
18/04/2023 13:08
April 18 (Reuters) - Adverum Biotechnologies Inc
ADVM.O :
* ADVERUM BIOTECHNOLOGIES GRANTED INNOVATIVE LICENSING AND
ACCESS
PATHWAY DESIGNATION IN THE UNITED KINGDOM FOR IXO-VEC FOR THE
TREATMENT OF WET AMD
Source text for Eikon: ID:nGNX6cyB1l
Further company coverage: ADVM.O
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)